Canada Pharmaceuticals & Healthcare Report
Was: $1030.00
Now: $875.00
You save: $155.00 (15%)
Canada Pharmaceuticals & Healthcare Report

The Canada Pharmaceuticals and Healthcare Report

Independent 5-year pharmaceutical and healthcare industry forecasts for Canada.

Original pharmaceutical and healthcare market research and pharmaceutical and healthcare sector trend analysis for the Canadian pharmaceutical and healthcare industry.

Competitive intelligence, Canadian pharmaceutical and healthcare company rankings and SWOT analyses on international and domestic pharmaceutical and healthcare companies in the Canadian market.

The Canada Pharmaceuticals and Healthcare Report has been researched at source and features the latest available data and forecasts to end- covering drugs and healthcare expenditure, the prescription, OTC and generics markets, and foreign trade; company rankings and competitive landscapes including multinational and national drugs companies; and analysis of latest industry news, trends and regulatory developments.

Business Monitor International’s Canada Pharmaceuticals and Healthcare Report provides industry professionals, market investors and corporate and financial services analysts with independent forecasts and competitive intelligence on the Canadian pharmaceutical and healthcare industry.

Key Benefits of Report

Coverage

Executive Summary & Industry SWOT

An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI’s forecast analysis, and taken together with BMI’s Economic and Business Environment SWOTS, give a complete overview of market climate.

Market Summary

Outline of market characteristics, growth factors, leading therapeutic segments and a competitivness of the market.

Regulatory Regime

Guide to and analysis of country intellectual property developments and pricing & reimbursement issues, which constitute the regulatory make-up of the market.

Industry Developments

Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D and patent legislation.

BMI 5-Year Industry Forecast

5-Year Forecasts to end- for all key industry indicators (see list below), supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:

Forecasts based on bespoke BMI economic modelling, using historical data sets of macroeconomic and industry variables to derive rigorous statistical relationships, anchored in advanced linear regression techniques.

BMI 5-Year Macroeconomic Forecasts

BMI forecasts for all headline macroeconomic indicators, including:
Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt

Competitive Landscape & Profiles

Intelligence on the market position of major MNC power houses and indigenous companies. BMI profiles key research-based companies. Company SWOTS are provided for all key strategic players, complete with a company activity overview, its leading products and analysis of business opportunities.

Canada Pharmaceuticals & Healthcare Report
Was: $1030.00
Now: $875.00
You save: $155.00 (15%)
Table of Contents

Chapter - Executive Summary

SWOT Analysis
Canada Pharmaceuticals And Healthcare Industry SWOT
Canada Political SWOT
Canada Economic SWOT

Chapter - Pharmaceutical Business Environment Ratings

Regional Pharma Business Environment Ratings
Limits Of Potential Returns
Risks To Realisation Of Returns

Chapter - Canada – Market Summary

Regulatory Regime
Pricing Regime And Reimbursement Issues
Reimbursement Regime
Recent Pricing and Reimbursement Developments

Chapter - Industry Developments

Epidemiology
Healthcare Sector
Health Expenditure
Table: Sustainability Of Public Health Expenditure And Pharmaceutical Approval Indicators
National Pharmaceuticals Strategy
Pharmaceutical Industry
Recent Company Activity
Pharmaceutical Re-import Policy
Research And Development Sector
Biotechnology
Medical Devices Industry
Recent Developments In The Medical Devices Industry

Chapter - Industry Forecast Scenario

Overall Market Forecast
Table: Canada – Drug Market Indicators, Historical Data And Forecasts
Key Growth Factors – Industry
Table: Canada – Health Expenditure Indicators, Historical Data And Forecasts
Key Growth Factors – Macroeconomic
Table: Canada – Economic Activity
Prescription Market Forecast
Table: Canada – Prescription Market Indicators, Historical Data And Forecasts (US$mn unless otherwise stated)
Patented Market Forecast
Table: Canada - Patented Market Indicators, Historical Data and Forecasts
Generics Market Forecast
Table: Canada - Generics Market Indicators, Historical Data and Forecasts
OTC Market Forecast
Table: Canada – OTC Market Indicators, Historical Data And Forecasts (US$mn unless otherwise stated)
Export/Import Forecasts
Table: Canada - Pharmaceutical Trade Indicators, Historical Data and Forecasts (US$mn)
Medical Devices Forecast
Table: Canada – Medical Device Market Forecast, Historical Data And Forecasts (US$mn unless otherwise stated)
Other Healthcare Data
Table: Canada – Other Health And Healthcare Indicators, Historical Data And Forecasts

Chapter - Competitive Landscape

Table: Canada's Leading Generics Firms, 2006

Chapter - Company Profiles

Leading Multinational Manufacturers
Pfizer
Merck & Co
GlaxoSmithKline
Sanofi-Aventis
Novartis
Indigenous Manufacturers
Apotex

Chapter - Country Snapshot: Canada Demographic Data

Section 1: Population
Table: Demographic Indicators, 2005-2030
Table: Rural/Urban Breakdown, 2005-2030
Section 2: Education And Healthcare
Table: Education, 2000-2003
Table: Vital Statistics, 2005-2030
Section 3: Labour Market And Spending Power
Table: Employment Indicators, 2001-2006
Table: Consumer Expenditure, 2000-2012 (US$)
Table: Average Annual Manufacturing Wages, 2000-2012

Chapter - BMI Forecast Modelling

How We Generate Our Pharmaceutical Industry Forecasts
Pharmaceutical Business Environment Ratings Methodology
Ratings Overview
Table: Pharmaceutical Business Environment Indicators
Weighting
Table: Weighting Of Components
Sources
Canada Pharmaceuticals & Healthcare Report
Was: $1030.00
Now: $875.00
You save: $155.00 (15%)
Executive Summary

In BMI’s Business Environment Rankings for Q209, Canada is once again placed third out of the 10 markets surveyed in the Americas region, having been overtaken by Puerto Rico in Q408. Canada is ranked joint 9th in global terms, alongside South Korea, despite having received a slightly lower score than in the previous quarter. Overall, the value of the Canadian CAD26bn (US$25bn) market at consumer prices is expected to rise to just CAD29.9bn (US$24.1bn) in 2013, implying a low compound annual growth rate (CAGR) of 2.8%. The worsening of its position is mainly a function of the slowdown of the growth of its pharmaceutical market, which is negatively impacted by patent expirations and government driven cut-backs on drug spending. Additionally, regulatory shortcomings have in the past been responsible for no-launches of some innovative medicines, with approvals experiencing considerable delays.

Canada spent CAD15.7 (US$15.1bn) on patented drugs in 2008, as pharmaceutical products worth US$1.2bn lost patent protection in 2007, around four times the value of the expected patent expiries in 2008 and 2009. According to IMS Health, the number of new molecular entities (NMEs) launched in Canada in 2007 accounted for less that 0.3% of total sales. Moreover, the patented medicine price index revealed that manufacturers’ prices fell by 0.2% in 2006 after four years of consecutive growth. However, BMI believes that the proposed system of progressive licensing that shifts the focus from pre-market review to ongoing post-market evaluations should improve the position of patented drugs. If implemented, the changes should help remove some of the regulatory hurdles for experimental new drugs, although critics claim that in effect consumers will be used like ‘guinea pigs’.

In economic terms, Canada is also experiencing a marked slowdown, with BMI pencilling in a 1.4% real GDP contraction in 2009. The key to Canada's economic health is the US, and on that front, we are seeing increasing downside risks, which in turn put our Canadian forecasts in jeopardy. Although we have not seen the same signs of economic decline in Canada as we have recognised in the US, in both countries, economic indicators are pointing toward a potentially prolonged and deep recession. We are currently forecasting a mild rebound in H209 but Canada will find it difficult to avoid a negative full-year figure. This outlook will have clear implications for the Canadian healthcare market, given that public funding accounts for some 70% of the total expenditure.

On a positive note for medical devices manufacturers, in February 2009, the Government of Ontario, extended a US$29.6mn grant to Agfa HealthCare from its Next Generation of Jobs Fund. The fund aims to both support existing jobs and create some 100 new positions. However, BMI notes that nearly 87% of all research and development (R&D) jobs are already located in Quebec and Ontario, with the two provinces therefore highly vulnerable to economic downturn. Additionally, the strength of the Canadian dollar against the US dollar has caused problems for the export-focused manufacturing industry, which has also had to contend with the emergence of lower-cost manufacturing bases (such as Mexico), making investment in hi-tech medical devices all the more necessary.

Canada Pharmaceuticals & Healthcare Report
Was: $1030.00
Now: $875.00
You save: $155.00 (15%)
Read about our other Pharmaceuticals & Healthcare Reports

Africa

Algeria, Egypt, Kenya, Morocco, Nigeria, South Africa and Zimbabwe

Asia

Australia, Bangladesh, China, Hong Kong, India, Indonesia, Japan, Malaysia, Pakistan, Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam

Caribbean

Puerto Rico

Europe

Belarus, Belgium, Bulgaria, Croatia, Czech Republic, Estonia, France, Germany, Greece, Hungary, Italy, Kazakhstan, Latvia, Lithuania, Moldova, Netherlands, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Switzerland, Ukraine, United Kingdom and Uzbekistan

Latin America

Argentina, Brazil, Chile, Colombia, Mexico, Peru and Venezuela

Middle East

Bahrain, Iran, Israel, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, Turkey and United Arab Emirates

North America

United States
Business Monitor International Business Monitor International
A Market Leader in Country Risk, Industry Intelligence and Company Research

Mermaid House, 2 Puddle Dock, Blackfriars, London EC4V 3DS, UK

BUSINESS MONITOR INTERNATIONAL's country risk analysis and forecasts, market research on leading industries, and multinational company research is relied upon by corporates, banks, government departments and multilateral organisations in over 125 countries around the world.

Country Risk Analysis and Forecasts
BMI
has for 25 years specialised in political risk analysis, financial markets analysis, and macroeconomic forecasts on 175 global markets.

Industry Intelligence and Market Research
BMI's industry research covers Automotives; Banking; Chemicals; Defence & Security; Food & Drink; Freight Transport; Information Technology; Infrastructure; Insurance; Mining; Oil & Gas; Petrochemicals; Pharmaceuticals & Healthcare; Power; Telecommunications, and Tourism.

Company Research
BMI maintains a fully-researched 55,000-site database of multinational company subsidiaries located across global markets.